Clinical trial
An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)
Invitation only · Not applicable · 1 countries · Registry ID NCT01511393
Invitation onlyNot applicableObservational
What this study is about
This study is conducted in the United States of America (USA). The aim of the study is to monitor the number of annual new adult cases of medullary thyroid carcinoma (MTC) and to establish a registry for these new cases in order to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to Not listed
SexAll
Healthy volunteersNot accepted
ConditionDiabetes, Diabetes Mellitus, Type 2, Medullary Thyroid Carcinoma, Weight Management
Full registry criteria
Inclusion Criteria: * A record of medullary thyroid carcinoma (MTC) identified from state/regional population-based cancer registries * At least 18 years or older. There are no other inclusion or exclusion criteria.
Treatments and study arms
No treatment given
Other
None. Non-interventional study.
Primary outcomes
Annual incidence of MTC in the US to identify any possible increase related to the introduction of liraglutide, exenatide once-weekly, and other GLP-1 receptor agonists into the US market.Up to 15 years
Study locations
1 locations were listed when this page was built. The first 40 are shown.
United BioSource, LLC🇺🇸 Morgantown, West Virginia, United States